Abstract: The present invention provides a compound of the formula: ##STR1## such compounds are useful for inhibiting prostaglandin synthesis. Pharmaceutical compositions and methods for inhibiting prostaglandin synthesis are also disclosed.

Abstract: A method of synthesizing a compound having a 1,3-thiazolidin-4-one ring appended at the 2-position by a double bond to the active methylene position of a ketomethylene or malononitrile moiety, which comprises reacting the corresponding ketomethylene compound or malononitrile with an isothiocyanate in the presence of a base, reacting the resulting product with a haloacetic acid or haloacetic ester, followed by eliminating water or alcohol to form the 1,3-thiazolidin-4-one ring. A fragment necessary to complete a merocyanine, oxonol, hemicyanine, benzylidene, cinnamylidene or holopolar cyanine dye can be appended to the 1,3-thiazolidin-4-one ring to obtain the desired dye.

Abstract: A process for the production of of general formula I diethylenetriaminepentacarboxylic acid monoamide derivatives ##STR1## in which E.sup.1, E.sup.2 and Z have varying meanings.

Abstract: 3-(Phenylalkylaminoalkyloxy)-heteroaryl compounds having heart rate lowering and/or anti-ischemic effects, methods for their preparation and pharmaceutical compositions containing them are described. The compounds correspond to the general formula I ##STR1## or to the general formula XXXI ##STR2## in which the substituents have the meanings given in the specification.

Abstract: A process for producing an acrylic acid ester or a methacrylic acid ester having a benzoic acid group from a benzoic acid derivative having a hydroxyalkyl group in the presence of an acid catalyst without using an azeotropic solvent with water having a strong toxicity and also without using acrylic acid chloride which has a strong tearing property, is hard to be handled and generates a by-product in the reaction. In the above process, the solvent for the benzoic acid derivative consists essentially of (meth)acrylic acid.

Abstract: A pyridothiazineacetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and a preparation for the prevention and treatment of the complications of diabetes, containing the same.The pyridothiazineacetic acid compound and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as a preparation for the prevention and treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly, cataract and neurosis. In addition, the production method of the present invention enables efficient production of said pyridothiazineacetic acid compound.

Abstract: Novel thiadiazole compounds are provided, which are effective as proton pumps inhibitors, useful in treating peptic ulcers by inhibition of the proton pump enzyme H.sup.+ /K.sup.+ -ATPase. The compounds are 3-substituted 1,2,4-thiadiazolo ?4,5-.alpha.!benzimidazole and 3-substituted imidazo?1,2-d!-1,2,4-thiadiazoles corresponding to the general formula: ##STR1## where X and Z either represent an optionally substituted benzene ring fused to the diazole nucleus, or represent a variety of independent chemical groupings (hydrogen, lower alkyl, halo, etc.) and Y is an electronegative group.

Abstract: Compounds of formula (I), wherein A is selected from (a), (b), (c), (d), (e), (f) and B is selected from (g), (h), and (i), wherein W is a carbonyl, sulphonyl or sulphinyl group, and X is a carbonyl, sulphonyl or sulphinyl group or --C(O)--CH.sub.2 -- (in which the carbonyl group is bonded to Y), provided that at least one of W and X contains carbonyl, Y is R.sub.9 --O-- or R.sub.9 --N(R.sub.10)--, Z is selected from (i), (ii), (iii), (iv) or Z is absent and W is H, with a number of provisions and phamaceutically acceptable salts thereof are ligands at CCK and/or gastrin receptors.

Abstract: Processes are disclosed for the recovery of 1,4-dioxanone by melt crystallization from a feed containing impurities capable of initiating the polymerization of 1,4-dioxanone, e.g., diethylene glycol. The processes of the present invention utilize melt crystallization in a cyclic process involving the steps of (i) crystallizing the 1,4-dioxanone out of the feed at a temperature below its melting point and removing a liquid residue containing a higher concentration of impurities, (ii) partially melting the crystallized 1,4-dioxanone to further remove impurities and (iii) thereafter, melting the remaining crystallized 1,4-dioxanone and recovering the melted product. The crystallization process can be repeated as required to achieve the desired purity. The purity of the product obtained is typically 99.5 wt %, 1,4-dioxanone or higher. The purified 1,4-dioxanone is useful, for example, as a monomer in the production of polydioxanone.

Abstract: A compound of formula I ##STR1## in which Ar.sub.1 is naphthyl and phenyl, quinolyl or isoquinolyl optionally substituted; Ar.sub.2 is phenyl or thienyl optionally substituted; R.sub.1, R.sub.2 and R'.sub.2 are independently of each other H or (C.sub.1 -C.sub.4)alkyl or R.sub.1 represents a bond and N is covalently bonded to Ar.sub.2, and optionally R.sub.2 and R'.sub.2 form a double bond, or R.sub.1 or R.sub.2 is covalently bonded to Ar.sub.2 and represents a (C.sub.1 -C.sub.3 )alkylene; R.sub.3 and R.sub.4 are independently of each other H or (C.sub.1 -C.sub.4)alkyl or form, with the nitrogen atom to which they are attached pyrrolidine, ppiperidine, or hexahydroazepine; Z.sub.1 represents (C.sub.1 -C.sub.12)alkylene, optionally interrupted by a radical selected from the group consisting of (C.sub.5 -C.sub.7)cycloalkyl and phenyl or substituted with a radical selected from the group consisting of (C.sub.5 -C.sub.7)cycloalkyl and phenyl; Q.sub.1 is selected from the group consisting of methyl, amino, (C.sub.

Abstract: A method for producing an alkylthiobenzamide by carrying out a reaction of a halobenzamide with an alkanethiol in the presence of a base in a heterogeneous solvent; a method for producing an alkylsulfinylbenzamide by carrying out a reaction of an alkylthiobenzamide with a halogen in a heterogeneous solvent; a method for producing an alkylsulfinylbenzamide by carrying out a reaction of a halobenzamide with an alkanethiol in the presence of a base in a heterogeneous solvent and a subsequent reaction with a halogen; and a method for producing a 1,2-benzisothiazol-3-one by carrying out a reaction of a 2-(alkylthio)benzamide with a halogenating agent.

Abstract: This application relates to new thiocarbamoyl compounds of the formula (I) ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings given in the description.

Abstract: The present invention provides a method of predicting whether an individual will be intolerant to the effect of fluoropyrimidines comprising the step of measuring the activity of orotate phosphoribosyltransferase activity in a biological sample obtained from said individual. Also provided is a method of determining a non-toxic dose of 5-fluoruracil in an individual in need of fluoropyrimidine therapy, comprising the step of measuring the activity of 5-fluoruracil phosphoribosyltransferase (FUPRTase) in a biological sample obtained from said individual.

Abstract: A method for the preservation of in vitro expanded epithelial sheets by incubation of the sheets in a cryopreserving solution characterized by lack of volume increase at the liquid-solid phase transition. The cryopreserving solutions comprise: a) polyethyleneglycols having molecular weight between 3 and 5 KD; and b) at least one cross-linking agent selected from polyols, polyamines, mono- or oligosaccharides, and polyethyleneglycols having molecular weight lower than 1 KD.

Abstract: A method for making a substituted benzene compound includes reacting a 2-substituted benzenesulfonate or the 2-substituted benzenesulfonate further substituted in the 3, 4 or 5-position with a lithium compound to form an intermediate; and reacting the intermediate with an electrophile to form a 2,6-disubstituted benzenesulfonate or a 2,6-disubstituted benzenesulfonate further substituted in the 3, 4 or 5-position.

Abstract: The invention relates to a method of producing optically active, 4-substituted (S)-2-Oxazolidinones, novel (S)-2-oxazolidinones, novel, optically active (S)-amino alcohols and the use of these compounds.

Abstract: Compounds of the formula ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the specification,Y is alkylene of 3 to 9 carbon atoms,R.sub.5 is alkoxycarbonyl, alkyltetrazolyl, phenyl or a heterocycle chosen from benzoxazolyl, benzathiazolyl, thiadiazolyl, imidazolyl, dihydroimidazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrazolyl, oxazolinyl, isoxazolyl, isothiazolyl, furyl, triazolyl, thiophenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or any of the above substituted with alkyl, alkoxyalkyl, cycloalkyl, halo alkyl, hydroxyalkyl, alkoxy, hydroxy, halo, furyl, thienyl, fluoroalkyl;or a pharmaceutically acceptable acid addition salts thereof; N-oxides thereof, are useful as antipirconaviral agents.

Abstract: A method of producing an ether-type thio-phospholipid of the formula (I): ##STR1## wherein: n is an integer of 13 to 17;A is C.sub.14 -C.sub.20 acyl group;G is a group selected from the group consisting of: ##STR2## which is useful as synthetic substrate of cytosolic phospholipase A.sub.2 inhibitors, said method being applicable to mass production of the compound (I), intermediates therefor and the preparation of the same are provided.

Abstract: 4-R.sup.4 -R.sup.5 -2-Saccharinylmethyl heterocyclic carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R.sup.4 -R.sup.5 -2-halomethylsaccharin with either a heterocyclic carboxylic acid in the presence of an acid-acceptor or the alkali metal salt of a heterocyclic carboxylic acid.

Abstract: Novel 2-substituted saccharins which inhibit the enzymatic activity of proteolytic enzymes, are useful in the treatment of degenerative diseases and have the formula ##STR1## wherein: L is --O--, --S--, --SO-- or --SO.sub.2 --;m and n are each independently 0 or 1;R.sub.1 is halo, lower-alkanoyl, 1-oxophenalenyl, phenyl or substituted phenyl, heterocyclyl or substitued heterocyclyl or, when L is --O-- and n is 1, cycloheptatrienon-2-yl or, whenL is --S-- and n is 1, cyano or lower-alkoxythiocarbonyl or, when L is --SO.sub.2 -- and n is 1, lower-alkyl or trifluoromethyl;R.sub.2 is hydrogen, lower-alkoxycarbonyl, phenyl or phenylthio; andR.sub.3 and R.sub.4 are each hydrogen or various substituents and processes for preparation and pharmaceutical compositions and method of use thereof are disclosed.